Cargando…

Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia

INTRODUCTION: Community acquired pneumonia (CAP) may present as life-threatening infection with uncertain progression and outcome of treatment. Primary aim of the trial was determination of the cut-off value of serum interleukin-6 (IL-6) and procalcitonin (PCT) above which, 30-day mortality in hospi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andrijevic, Ilija, Matijasevic, Jovan, Andrijevic, Ljiljana, Kovacevic, Tomi, Zaric, Bojan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073574/ https://www.ncbi.nlm.nih.gov/pubmed/24987476 http://dx.doi.org/10.4103/1817-1737.134072

Ejemplares similares

Prognostic Role of Monocyte Distribution Width, CRP, Procalcitonin and Lactate as Sepsis Biomarkers in Critically Ill COVID-19 Patients
por: Bajić, Dejana, et al.
Publicado: (2023)

Detection of premalignant bronchial lesions can be significantly improved by combination of advanced bronchoscopic imaging techniques
por: Zaric, Bojan, et al.
Publicado: (2013)

Association Between the Inflammatory Biomarkers and Left Ventricular Systolic Dysfunction in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease
por: Andrijevic, Ljiljana, et al.
Publicado: (2017)

Clinical trials in advanced stage lung cancer: a survey of patients' opinion about their treatment
por: Zaric, Bojan, et al.
Publicado: (2011)

Confidence level in venipuncture and knowledge on causes of in vitro hemolysis among healthcare professionals
por: Milutinović, Dragana, et al.
Publicado: (2015)

The effect of vitamin C on procalcitonin biomarker in community‐acquired pneumonia
por: Nikzad, Mahsa, et al.
Publicado: (2021)

Procalcitonin and CRP as Biomarkers in Discrimination of Community-acquired Pneumonia and Exacerbation of COPD
por: Çolak, Ayfer, et al.
Publicado: (2017)

Role of procalcitonin in diagnosis of community acquired pneumonia in Children
por: Ratageri, Vinod H., et al.
Publicado: (2022)

“Everything for Her!”
por: Andrijević Matovac, Vesna
Publicado: (2011)

Hemogram‐based decision tree models for discriminating COVID‐19 from RSV in infants
por: Dobrijević, Dejan, et al.
Publicado: (2023)

Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia
por: Self, Wesley H., et al.
Publicado: (2017)

Interleukin-5, interleukin-6, interferon induced protein-10, procalcitonin and C-reactive protein among mechanically ventilated severe community-acquired viral and bacterial pneumonia patients
por: Karhu, Jaana, et al.
Publicado: (2019)

Farewell
por: Matovac, Nika, et al.
Publicado: (2011)

Could platelet indices have diagnostic properties in children with COVID‐19?
por: Dobrijević, Dejan, et al.
Publicado: (2022)

Clinical Hematochemical Parameters in Differential Diagnosis between Pediatric SARS-CoV-2 and Influenza Virus Infection: An Automated Machine Learning Approach
por: Dobrijević, Dejan, et al.
Publicado: (2023)

Usefulness of Plasma Procalcitonin to Predict Severity in Elderly Patients with Community-Acquired Pneumonia
por: Kim, Ji Hye, et al.
Publicado: (2013)

CON: Procalcitonin does not have clinical utility in children with community-acquired pneumonia
por: Banerjee, Ritu
Publicado: (2021)

Biomarkers in Pneumonia—Beyond Procalcitonin
por: Karakioulaki, Meropi, et al.
Publicado: (2019)

Value of procalcitonin as a biomarker for postoperative hospital-acquired pneumonia after abdominal surgery
por: Abu Elyazed, Mohamed M, et al.
Publicado: (2017)

Frequency of COPD in health care workers who smoke
por: Kopitovic, Ivan, et al.
Publicado: (2017)

Pneumococcal nasopharyngeal carriage in children under 5 years of age at an outpatient healthcare facility in Novi Sad, Serbia during the COVID-19 pandemic
por: Petrović, Vladimir, et al.
Publicado: (2022)

Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study
por: Gaïni, Shahin, et al.
Publicado: (2006)

Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia
por: Cohen, Jérémie F., et al.
Publicado: (2012)

Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-Acquired Pneumonia
por: Stockmann, Chris, et al.
Publicado: (2018)

Utilization of serum procalcitonin as a biomarker in the diagnosis and treatment of children with bacterial hospital-acquired pneumonia
por: Wang, Wenlong, et al.
Publicado: (2020)

Biomarkers of Cardiac Dysfunction and Mortality from Community-Acquired Pneumonia in Adults
por: Chang, Catherina L., et al.
Publicado: (2013)

Interleukin-6 in blood and bronchoalveolar lavage fluid of hospitalized children with community-acquired pneumonia
por: Zhang, Yun, et al.
Publicado: (2022)

ROLE OF PROCALCITONIN IN PATIENTS WITH COVID-19 AND HOSPITAL-ACQUIRED PNEUMONIA
por: KUMAR, MYTHRI ANIL, et al.
Publicado: (2022)

Patient-related independent clinical risk factors for early complications following Nd: YAG laser resection of lung cancer
por: Perin, Branislav, et al.
Publicado: (2012)

Correlation between plasma peroxides and procalcitonin levels in patients with severe streptococcal community acquired pneumonia
por: Borrelli, E, et al.
Publicado: (2002)

Role of C-Reactive Protein and Procalcitonin in Differentiation of Tuberculosis from Bacterial Community Acquired Pneumonia
por: Kang, Young Ae, et al.
Publicado: (2009)

Procalcitonin guidance significantly reduces antibiotic duration in community-acquired pneumonia: the 'ProCAP' study
por: Christ-Crain, M, et al.
Publicado: (2005)

Diagnostic and Prognostic Values of Admission Procalcitonin Levels in Community–Acquired Pneumonia in an Intensive Care Unit
por: Boussekey, N., et al.
Publicado: (2005)

The potential of molecular diagnostics and serum procalcitonin levels to change the antibiotic management of community-acquired pneumonia
por: Gilbert, David, et al.
Publicado: (2016)

Procalcitonin Is Useful for Evaluating Patients with Ambiguous Presentation and for Early Discontinuation of Antibiotics in Community-acquired Pneumonia
por: Schuetz, Philipp
Publicado: (2020)

Diagnostic and Prognostic Roles of Procalcitonin and Other Tools in Community-Acquired Pneumonia: A Narrative Review
por: Ozbay, Sedat, et al.
Publicado: (2023)

Procalcitonin is not an independent predictor of 30-day mortality, albeit predicts pneumonia severity in patients with pneumonia acquired outside the hospital
por: Akagi, Takanori, et al.
Publicado: (2019)

Biomarkers in Pediatric Community-Acquired Pneumonia
por: Principi, Nicola, et al.
Publicado: (2017)

The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy
por: Mira, Jean-Paul, et al.
Publicado: (2008)

Procalcitonin and C-Reactive Protein in Hospitalized Adult Patients With Community-Acquired Pneumonia or Exacerbation of Asthma or COPD
por: Bafadhel, Mona, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_6jaud89tqecpqulg6gmmsd9ia8